60 Degrees Pharmaceuticals (NASDAQ:SXTP) Announces Earnings Results, Misses Estimates By $0.16 EPS

60 Degrees Pharmaceuticals (NASDAQ:SXTP) released its quarterly earnings results on Friday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16), FiscalAI reports. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.18 million.

60 Degrees Pharmaceuticals Trading Up 1.3%

60 Degrees Pharmaceuticals stock traded up $0.01 during trading hours on Friday, hitting $1.20. 150,822 shares of the stock traded hands, compared to its average volume of 1,870,604. 60 Degrees Pharmaceuticals has a one year low of $1.05 and a one year high of $8.62. The firm’s 50-day moving average price is $1.47 and its two-hundred day moving average price is $2.02. The company has a market cap of $3.18 million, a PE ratio of -0.13 and a beta of 2.54.

Analyst Ratings Changes

SXTP has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, June 24th. Ascendiant Capital Markets dropped their price target on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating for the company in a research note on Friday, May 22nd. Finally, HC Wainwright cut shares of 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $13.85.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.